FDA Permits Marketing of First SARS-CoV-2 Diagnostic Test Using Traditional Premarket Review Process

SILVER SPRING, Md., March 17, 2021 /PRNewswire/ -- Today, the U.S. Food and Drug Administration granted marketing authorization of the BioFire Respiratory Panel 2.1 (RP2.1), a diagnostic test for the simultaneous qualitative detection and identification of multiple respiratory viral and...

from PR Newswire: https://ift.tt/3tvxkB1